Codexis, Inc.
200 Penobscot Drive
Redwood City, CA 94063
United States
Tel: 650-421-8100
Website: http://www.codexis.com/
About Codexis, Inc.
Codexis is a leading enzyme engineering company leveraging our proprietary CodeEvolver® technology platform to discover and develop novel, high performance enzymes for three healthcare industry pillars: pharmaceutical manufacturing, life sciences, and biotherapeutic discovery & development. The enzymes we produce aim to solve real-world challenges associated with small molecule pharmaceuticals manufacturing, nucleic acid synthesis and genomic sequencing, and - as biotherapeutic candidates - they have the potential to treat challenging diseases. To meet this goal, we look for individuals who are driven, eager to grow and ready to embrace meaningful challenges. We empower employees to be authentic, ambitious, agile and have the courage to take action where they can make a positive impact. Whether you are driven by science, or a different area of expertise, we need you to help us create a brighter future.
Are you ready to join our mission to fight rare diseases? Are you interested in enhancing protein optimization and production? Do you have a passion to help people have better quality of life? Come be part of the Codexis, Inc. team where every day we get to unlock the power of proteins®!
Codexis uses our world-leading CodeEvolver® protein engineering platform to discover novel therapies for the treatment of genetic disorders and other debilitating disease and to develop custom enzymes for a wide range of applications. We engineer proteins with high efficacy and safety with the goal of delivering the therapeutic to patients as an enzyme replacement, mRNA, or gene therapy.
But we can't do it without YOU!
We are rapidly growing, and we are presently seeking to expand our pipeline and diversify applications of our technology platform. We have a number of opportunities for passionate scientists that want to do something
104 articles about Codexis, Inc.
-
Codexis to Report First Quarter 2024 Financial Results on May 2
4/18/2024
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2024 on Thursday, May 2, 2024, following the close of market.
-
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
4/11/2024
Codexis, Inc., a leading enzyme engineering company, announced the appointment of Carole Cobb, MBA, to the Company’s Strategic Advisory Board.
-
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
2/28/2024
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023, and provided a business update.
-
Codexis to Participate in TD Cowen 44th Annual Health Care Conference
2/26/2024
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44th Annual Health Care Conference, being held March 4-6, 2024, in Boston, Massachusetts.
-
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
2/26/2024
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive, global license for the Company’s newly engineered double-stranded DNA (dsDNA) ligase for next-generation sequencing (NGS) library preparation and the Company’s EvoT4™ DNA ligase.
-
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board
2/20/2024
Codexis, Inc. today announced the appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to the Company’s Strategic Advisory Board (SAB), joining John Maraganore, PhD, the founder and former Chief Executive Officer of Alnylam Pharmaceuticals.
-
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
2/14/2024
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2023 on Wednesday, February 28, 2024, following the close of market.
-
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
12/27/2023
Codexis, Inc. announced it has entered into a purchase agreement with Nestlé Health Science, a globally recognized leader in the field of nutritional science, for CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insufficiency.
-
Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform
12/13/2023
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has achieved gram-scale synthesis with its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology.
-
Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase
12/13/2023
Codexis, Inc. announced it has entered into an agreement with Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, whereby Aldevron will acquire a global exclusive license to Codexis’ Codex® HiCap RNA Polymerase.
-
Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing
12/11/2023
Codexis, Inc. hosted a virtual Key Opinion Leader event on Friday, December 8, 2023, to discuss the growth of RNA interference therapeutics as a modality, the manufacturing landscape and the potential role for the Company’s Enzyme-Catalyzed Oligonucleotide Synthesis™ platform to enable commercial-scale production of RNAi therapeutics.
-
Codexis to Participate in 35th Annual Piper Sandler Healthcare Conference
11/14/2023
Codexis, Inc., a leading enzyme engineering company, announced the Company will attend the 35th Annual Piper Sandler Healthcare Conference, being held November 28-30, 2023, in New York, New York.
-
Research associates are always in demand. Check out these top companies currently hiring RAs.
-
Codexis Reports Third Quarter 2023 Financial Results
11/2/2023
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the third quarter ended September 30, 2023, and provided a business update.
-
Codexis to Participate in Upcoming November 2023 Healthcare Conferences
10/31/2023
Codexis, Inc., a leading enzyme engineering company, announced that management will participate in four upcoming investor conferences.
-
Codexis to Present Update on ECO Synthesis™ Platform at TIDES Europe
10/26/2023
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced a presentation highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES Europe annual meeting taking place in Amsterdam, Netherlands and virtually October 30-November 1, 2023.
-
Codexis to Report Third Quarter 2023 Financial Results on November 2
10/19/2023
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the third quarter of 2023 on Thursday, November 2, 2023, following the close of market.
-
Codexis CEO Stephen Dilly Wins Prestigious 2023 Bloom Burton Award
9/29/2023
Codexis, Inc., a leading enzyme engineering company, announced President and Chief Executive Officer Stephen Dilly, MBBS, PhD, has been named the winner of the prestigious 2023 Bloom Burton Award.
-
Codexis CEO Stephen Dilly Named as Finalist of 2023 Bloom Burton Award
9/18/2023
Codexis, Inc., a leading enzyme engineering company, announced Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, has been named a finalist for the prestigious 2023 Bloom Burton Award.
-
Codexis to Participate in Cantor Global Healthcare Conference
9/12/2023
Codexis, Inc., a leading enzyme engineering company, announced the Company will attend the Cantor Global Healthcare Conference, being held September 26-28, 2023, in New York, New York.